Raloxifene News and Research

RSS

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

First Edition: January 10, 2014

Today's headlines include reports about Maryland's plan to reduce hospital spending.

10 Jan 2014

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet.

13 Dec 2013

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Scientists found genetic variations that could be used to identify women who are most likely to benefit from a certain type of breast cancer prevention drug—and who should avoid it.

3 Jul 2013

Gene variants may predict which women are most likely to benefit from breast cancer therapy

In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy—and which should avoid it.

14 Jun 2013

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.

14 Jun 2013

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

14 Jun 2013

Web-based decision guide reduces uncertainty about breast cancer prevention options

When women at high risk of breast cancer viewed a customized web-based decision guide about prevention options, they were more likely to make a choice about prevention and to feel comfortable with their choice, a new study finds.

16 Apr 2012

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.

10 Aug 2011

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.

6 Jun 2011

Drugs for prevention of breast cancer

According to an international panel of cancer experts, women at high risk of developing breast cancer should be given preventative drugs. The experts write in the Lancet Oncology adding, drugs such as tamoxifen could reduce the chances of developing breast cancer. They suggest that this would be something similar to prescribing statins to patients at risk of heart disease. But tamoxifen has been linked with womb cancer, blood clots and stroke.

28 Mar 2011

Drugs can prevent risk of breast cancer in women, experts say

Drugs could be used to prevent breast cancer in women at high risk of the disease in the same way that statins are used for heart disease if trials looking at ways of predicting risk are successful, according to an international panel of cancer experts.

28 Mar 2011

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

In an update to its 2002 recommendation, the U.S. Preventive Services Task Force now recommends that all women ages 65 and older be routinely screened for osteoporosis.

18 Jan 2011

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.

9 Dec 2010

Women and cancer today

Experts have warned that women who have their breasts removed out of fear of a high hereditary risk of breast cancer may be doing so needlessly. Genetic tests like for the BRCA mutations have predicted a high risk of getting breast cancer in women with many breast cancer sufferers among their first degree relatives. Earlier studies suggest the risk of the mutation to predict the cancer 87% of the time. Now experts want that this is an overestimate.

11 Nov 2010

$Medtronic's Xpander II receives FDA clearance for vertebral compression fractures$

Medtronic's Xpander II receives FDA clearance for vertebral compression fractures

Medtronic Inc. today announced Food and Drug Administration (FDA) clearance of the Kyphon Xpander II Inflatable Bone Tamp (IBT) for the treatment of vertebral compression fractures with minimally invasive Kyphon Balloon Kyphoplasty

22 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Raloxifene drug may be useful in treating kidney disease in women: Study

The osteoporosis drug raloxifene may be useful in treating kidney disease in women, suggests a new study led by Michal Melamed, M.D., M.H.S., assistant professor of medicine and epidemiology & population health at the Albert Einstein College of Medicine of Yeshiva University.

7 Oct 2010

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

Medtronic Inc. today announced the launch of the new KYPHON® Express™ Curette for scraping or scoring bone in the spine, including during treatment of vertebral compression fractures with minimally invasive KYPHON® Balloon Kyphoplasty.

6 Oct 2010

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

4 Oct 2010

Raloxifene News and Research

First Edition: January 10, 2014

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Gene variants may predict which women are most likely to benefit from breast cancer therapy

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Web-based decision guide reduces uncertainty about breast cancer prevention options

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Drugs for prevention of breast cancer

Drugs can prevent risk of breast cancer in women, experts say

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Women and cancer today

Medtronic's Xpander II receives FDA clearance for vertebral compression fractures

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Raloxifene drug may be useful in treating kidney disease in women: Study

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News